This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2015 by Cytonics Corporation.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Cytonics Corporation
ClinicalTrials.gov Identifier:
NCT02210468
First received: July 23, 2014
Last updated: August 19, 2015
Last verified: August 2015
  Purpose
The mechanism of Osteoarthritis (OA) is complex, however the investigators know that cartilage breakdown follows changes in certain cells in the cartilage called chondrocytes, leading to proteases that break down cartilage. There is a protein in the human blood called alpha-2-macroglobulin that can trap these proteases and prevent the breakdown of cartilage. Cytonics developed a device that use the patient's own blood to remove all cells and concentrate alpha-2-macroglobulin to be injected in the painful knee due to osteoarthritis.

Condition Intervention Phase
Pain Osteoarthritis Device: APIC-CF, 4 cc Device: APIC-CF, 2 cc Other: Placebo Comparator: Saline Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I/II, Multicenter, Double-Blind, Placebo-controlled Safety and Efficacy Study to Evaluate APIC-CF Therapy for Mild to Moderate Primary Osteoarthritis of the Knee

Resource links provided by NLM:


Further study details as provided by Cytonics Corporation:

Primary Outcome Measures:
  • Reduction in pain after 8 weeks [ Time Frame: 8 weeks ]
    Statistically significant reduction in pain after 8 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score

  • Reduction in pain while walking at 8 weeks [ Time Frame: 8 weeks ]
    Statistically significant reduction in pain while walking after 8 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score


Secondary Outcome Measures:
  • Reduction in pain after 2 weeks [ Time Frame: 2 weeks ]
    Statistically significant reduction in pain after 2 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score.

  • Reduction in pain while walking at 2 weeks [ Time Frame: 2 weeks ]
    Statistically significant reduction in pain while walking after 2 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score

  • Reduction in pain at 24 weeks [ Time Frame: 24 weeks ]
    Statistically significant reduction in pain after 24 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score

  • Reduction in pain while walking after 24 weeks [ Time Frame: 24 week ]
    Statistically significant reduction in pain while walking after 24 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score


Estimated Enrollment: 300
Study Start Date: May 2015
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: APIC-CF 4cc,
APIC-CF 4cc, once at first day
Device: APIC-CF, 4 cc
Experimental: APIC-CF, 2cc
APIC-CF, 2cc, one at first day
Device: APIC-CF, 2 cc
Placebo Comparator: Saline Other: Placebo Comparator: Saline
Placebo Comparator: Saline

  Eligibility

Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient provides signed written informed consent
  2. The patient is willing and able to complete effectiveness and safety questionnaires and is able to read and understand study instructions in English.
  3. Patient is a male or female aged between 21 - 70 years of age at the time of informed consent.
  4. Patient is ambulatory (assistive devices allowed if used 4 weeks or more prior to Screening).
  5. Patient has symptomatic OA in the target knee
  6. Patient has a radiographic confirmation of OA at the target knee prior to screening with a grade II or III score on the K-L grading scale (Kellgren, 1957)using radiographs performed within 24 weeks of Screening
  7. The patient has knee pain as demonstrated by a score of ≤3 on the KOOS pain subscale
  8. The patient has venous access sufficient for APIC-CF production

Exclusion Criteria:

  1. The patient has any of the following:

    • Grade 4 score on the K-L grading scale for the target knee
    • Grade 3 score on the K-L grading scale and exhibits at least one Grade 4 characteristic (large osteophytes, marked narrowing of joint space, severe sclerosis, or definite deformity of bone contour).
    • Acute fracture of the lower limb.
  2. Medical history of severe bone disease (e.g., osteoporosis, osteonecrosis, joint deformity, instability, or septic arthritis).
  3. The patient is categorized as grossly obese, defined as body mass index (BMI) greater than 35 kg/m2
  4. Hemoglobin values <11 g/dL
  5. Pregnant or breastfeeding women
  6. Has clinically apparent tense effusion of the target knee.
  7. Has had chondrocyte transplantation or reconstruction of ligaments in the target knee.
  8. Has received an intra-articular injection(s) into any joint (e.g., corticosteroids or chondroprotective agents) within 60 days prior to Screening. Subjects receiving a corticosteroid injection during the study will be withdrawn from the study.
  9. Has had surgery to the target knee within 12 months or arthroscopy of the target knee within 90 days prior to Screening.
  10. Has an inflammatory disease of either knee other than OA (e.g., rheumatoid arthri septic arthritis).
  11. Has another disease that can affect the health of the knee (e.g., chronic hemochromatosis; sickle cell anemia; arthropathies of systemic diseases such as chondrocalcinosis, gout, pseudogout, psoriasis, hemophilia, and infectious diseases of the joints).
  12. Has significant joint infection in the target knee or inflammatory or skin disorder in the injection area of the target knee.
  13. Septic arthritis in any joints within 1 year prior to screening;
  14. Has fibromyalgia, anserine bursitis, lumbar radiculopathy, neurogenic or vascular claudication, vascular insufficiency of lower limbs, or peripheral neuropathy severe enough to interfere with the study evaluations.
  15. Patella femoral instability
  16. Patients with a history of cartilage allograft, autograft or microfracture in the study knee
  17. Patients with a history of any type of blood coagulation or bleeding disorder, currently taking warfarin or other parental anticoagulant therapy or history of DVT/PE during <1 year of Screening.
  18. Has a systemic or other disease or significant liver function test result from screening that, in the opinion of the investigator, would interfere with study evaluation or have an impact on the balance of benefits and risks of study treatment.
  19. Diseases that may interfere:

    • type 1 diabetes
    • immunodeficiency syndrome
    • significant cardiovascular, renal, or liver disease
    • severe anemia
    • severe thrombocytopenia
    • severe infectious disease with or without fever.
    • any significant chronic skin disorders, active skin or soft tissue infection that could interfere with the evaluation of the injection site.
    • mal-alignment/deformity of the leg
    • active asthma that may require periodic treatment with steroids during the study period
    • active malignancy receiving treatment, or prior history of any malignancy, with the exception of basal cell carcinoma of the skin treated more than 1 year ago
  20. Patients with psychiatric or neurological disorders including cognitive impairment or inability to provide informed consent
  21. Incarcerated or confined patients
  22. Medical-legal, personal injury, ongoing litigation or worker's compensation claim
  23. History of drug abuse
  24. Use of investigational drug, device, or biologic within 12 weeks of screening
  25. Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02210468

Contacts
Contact: Gaetano Scuderi, MD 561-575-4451 ext 1 scuderimd@aol.com

Locations
United States, Maryland
IRC Clinical Recruiting
Townsend, Maryland, United States, 21204
Contact: Kendra Barton, RN, BSN    443-275-1599    kendra.barton@ircclinical.com   
Sponsors and Collaborators
Cytonics Corporation
  More Information

Responsible Party: Cytonics Corporation
ClinicalTrials.gov Identifier: NCT02210468     History of Changes
Other Study ID Numbers: Cyt300-01
Study First Received: July 23, 2014
Last Updated: August 19, 2015

Keywords provided by Cytonics Corporation:
Osteoarthritis
Protease Inhibitors
Alpha-2-macroglobulin
Autologous treatment
APIC-CF
Pain due to Mild to Moderate osteoarthritis (OA) of the knee

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on August 18, 2017